Determining Individualized Cancer Therapy in Pancreatic Cancer

Pancreatic Neoplasms Clinical Trial

— PREDICT-PANC  

Official title:

Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05914987
• Other study ID #: PRO00048019
• Status: Recruiting
• Start date: December 4, 2023
• Est. completion date: August 1, 2033

Study information

• Verified date: February 2024
• Source: Medical College of Wisconsin
• Contact: Cancer Center Clinical Trials Office
• Phone: 1-414-805-8900
• Email: cccto[@]mcw.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: August 1, 2033
• Est. primary completion date: August 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years.

• Pathologically confirmed pancreatic cancer.

• Ability to understand a written informed consent document and the willingness to sign it

Exclusion Criteria:

• Age <18 years.

• Primary cancer diagnosis other than pancreatic cancer.

Related Conditions & MeSH terms

• Pancreatic Neoplasms

Intervention

Other:
• Targeted Therapy
Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.

Locations

Country	Name	City	State
United States	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Receiving Targeted Therapy	This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.	5 years